Continuum's 15min Chart: Bearish Marubozu and KDJ Death Cross Triggered

Continuum's 15-minute chart recently exhibited a KDJ Death Cross and Bearish Marubozu pattern on October 17, 2025, at 12:45. This indicates a shift in the momentum of the stock price towards a downward trajectory, with a potential for further decline. The dominance of sellers in the market suggests that bearish momentum is likely to persist.

On October 17, 2025, Xortx Therapeutics (XRTX) experienced a notable shift in its stock price momentum, with a KDJ Death Cross and Bearish Marubozu pattern indicating a potential downward trajectory. This technical analysis suggests that the stock price may continue to decline, driven by increased selling pressure.

Recent Developments

Acquisition of Renal Anti-Fibrotic Therapeutic Program
Xortx Therapeutics recently announced the acquisition of a renal anti-fibrotic therapeutic program from Vectus Biosystems, according to a StockTitan report https://www.stocktitan.net/news/XRTX/. This strategic move aims to enhance the company's pipeline for treating progressive kidney diseases and metabolic disorders.

Investor Webinar and Q&A Session
The company has scheduled an exclusive live investor webinar and Q&A session on September 10, 2025, at 4:15 pm ET. StockTitan also reported that CEO Dr. Allen Davidoff will discuss the company's innovative therapies for cardiorenal conditions, including the late-stage program for allopurinol-intolerant gout, XRx-026 (XORLO™).

IND Preparation for XORLO™
Xortx Therapeutics has initiated the preparation of an Investigational New Drug (IND) application for XRx-026 (XORLO™). The same StockTitan report noted that the company expects to submit the IND in H2 2025, following an April 2025 Type B meeting with the FDA.

Market Outlook

The recent technical indicators suggest a bearish trend for XRTX stock. The KDJ Death Cross and Bearish Marubozu pattern indicate a potential continuation of the downward momentum, driven by the dominance of sellers in the market.

Conclusion

Xortx Therapeutics continues to make strides in its pipeline for treating progressive kidney diseases and metabolic disorders. However, the recent technical indicators suggest a bearish trend, potentially leading to further stock price declines. Investors should closely monitor the company's regulatory submissions and clinical trial progress to assess the stock's potential for recovery.

References

StockTitan report — https://www.stocktitan.net/news/XRTX/